Australian biotech HaemaLogiX has been recognised as a rising leader in advanced cancer therapies, taking home the award for 'Most Promising CAR-T Pipeline in APAC' at the Asia Pacific CGT Excellence Awards 2025, held in Singapore.
The award recognises companies demonstrating outstanding innovation and translational potential in the rapidly evolving CAR T-cell therapy sector. For HaemaLogiX, it affirms the company’s efforts to develop novel immunotherapies targeting blood cancers, with a particular focus on multiple myeloma, the world’s second most common blood cancer.
“This award is wonderful recognition of not just our science, but also the dedication and vision that drives our work,” said Rosanne Dunn, Founder and Chief Scientific Officer of HaemaLogiX. “We’re honoured to be recognised among the region’s top innovators — all striving to redefine what’s possible in CAR T-cell therapy. We’re more determined than ever to advance transformative therapies, particularly for multiple myeloma, a disease for which there is currently no cure.”
HaemaLogiX’s approach is based on binding to unique antigens on cancerous plasma cells, kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA), that are not present on normal plasma cells. By targeting these markers, the company aims to achieve precise efficacy with reduced off-tumour toxicity, preserving immune function and offering a clear differentiation from current treatment options.
Globally, multiple myeloma accounts for around 188,000 new cases each year, with outcomes remaining poor despite advances in therapy. About 42 per cent of patients die within five years of diagnosis, underscoring the urgent need for new treatments.
The recognition from the Asia Pacific CGT Excellence Awards places HaemaLogiX among the region’s most promising innovators in advanced therapies and highlights its potential to contribute meaningfully to the future of CAR T-cell therapy in APAC and beyond.